Dipu Diagnostics Completes Over RMB 100 Million Series B Financing to Accelerate R&D and Clinical Implementation of Novel High-End Genetic Testing Products
March 14,Zhejiang Digena Diagnostic Technology Co. , Ltd.(hereinafter referred to as “Digena Diagnostics”) announced the completion of its Series B financing round, exceeding RMB 100 million, with a post-money valuation nearing RMB 1 billion. This round of financing was led byShanghai Pudi (Prosperico Ventures)Lead Investor,Taikun FundandRushan Growth Venture Capital (Rushan Capital)Co-investment. The financing proceeds will be primarily used for the research, development, and production of new high-end genetic testing products, regulatory registration and filings, and the comprehensive advancement of clinical application strategies.
Digena Standard GMP Production Base
Digena Diagnostics, established in 2018, is an innovative IVD company specializing in advanced genetic testing technologies. Its core team members possess extensive experience in the field of molecular diagnostics and are elite professionals honed by leading global companies in the industry.
The DP-TOF Time-of-Flight Nucleic Acid Mass Spectrometer, independently developed and manufactured by Digena Diagnostic, is the first approved general-purpose nucleic acid mass spectrometry system in China. It serves as an accurate, cost-effective, simple, and convenient medium-throughput genetic testing platform, and has been recognized as one of the first major technical equipment sets in China and appraised as a new industrial product in Zhejiang Province. The newly introduced nanopore single-molecule sequencing technology functions as a point-of-care testing (POCT) solution for high-throughput sequencing, offering a portable genetic testing platform characterized by long reads, real-time analysis, and on-demand sequencing. Both platforms facilitate hospital-based testing with relative ease, representing clinically accessible advanced genetic testing technologies with broad application prospects in clinical practice.
Qian Tingzhi, Founding Partner of Prosperico VenturesDigena Diagnostic: Aligning with clinical needs, Digena Diagnostic has strategically established a medium-throughput genetic testing platform represented by nucleic acid mass spectrometry and a single-molecule sequencing platform represented by nanopore sequencing. The company possesses comprehensive capabilities integrating original hardware innovation, software technology development, reagent development, and testing services, along with strong commercialization capabilities. Digena Diagnostic provides clinical precision diagnostic solutions in multiple fields, including genetic diseases, pharmacogenomics, oncology, and infectious diseases, benefiting a broad patient population.
Zheng Mingming, Investment Director at Rushan CapitalStatement: As a cutting-edge technology transitioning from research to clinical application, mass spectrometry has long been a key investment focus for Rushan Capital. Nucleic acid mass spectrometry, with its unique advantages of medium-throughput capacity, high accuracy, and low cost, aligns perfectly with clinical needs and is widely used across numerous clinical fields. The core team at Digena Diagnostic boasts extensive industry experience, strong cohesion, and robust execution capabilities. Within a remarkably short period, the company secured China’s first registration certificate for general-purpose nucleic acid mass spectrometry and established its ecosystem and sales channels. As the nucleic acid mass spectrometry ecosystem matures and the portfolio of related IVD products expands, it is expected to rapidly drive an explosion in the clinical market for this technology.
Digena Diagnostic seeks to collaborate with experts and peers across various fields to develop new clinical testing products that meet patient needs, leveraging its two advanced genetic testing platforms. Together, we aim to build a high-end ecosystem for genetic testing platform applications, ensuring that everyone has access to accurate, affordable, rapid, and simple genetic testing services, thereby better safeguarding the health of the Chinese population.
Digena Provincial High-Tech Enterprise R&D Center
Prosperico Ventures is an investment institution focused on the healthcare sector, dedicated to value investing by identifying high-quality enterprises along the healthcare industry chain and facilitating their rapid growth. Since its inception, Prosperico Ventures has continuously refined its investment layout in niche sectors such as innovative medical devices, pharmaceutical R&D, precision medicine, and chain-based medical services. Its portfolio includes Lenor Medical, Antegen Biotech, PhenoGene Biosciences, Genetron Health, Fourier Intelligence, and Jionuo Medical.
Taikun Fund is a biomedical industry fund jointly established by Tigermed, Hangzhou Capital, and Hangzhou Gaoke Sci-Tech Innovation. Leveraging Tigermed’s industrial layout in clinical CRO services and aligning with the strategic development of Hangzhou’s pharmaceutical industry, the fund operates on a market-oriented basis. Focusing on the life and health industry, it prioritizes investments in innovative medical devices, biopharmaceuticals, healthcare services, healthcare informatics, digital therapeutics, intelligent manufacturing, and nutritional health enterprises.
Crestvalue Capital (CRESTVALUE) is a venture capital firm operating on market-oriented principles, specializing in equity investments in high-tech, high-growth enterprises. It focuses on emerging sectors such as broad security, advanced intelligence, comprehensive healthcare, and new-energy vehicles. With Hangzhou, Shenzhen, and Beijing as its core investment hubs, the firm extends its reach to surrounding regions. To date, it has invested in over 100 companies distinguished by proprietary technologies and innovative business models, possessing high growth potential and promising returns, thereby cultivating a portfolio of star projects that have exerted significant industry influence and substantially driven productivity gains. The firm has been elected as a vice-chairman unit of the Equity and Venture Capital Professional Committee of the Investment Association of China, a vice-chairman unit of the Zhongguancun Equity Investment Association, and a vice-chairman unit of the Zhejiang Venture Capital Association. It has also been honored as one of the “Top 100 Best Venture Capital Firms in China 2019” by Financing China and named “China’s Venture Capital Firm of the Year 2019,” while being consecutively ranked among the “Top 10 Venture Capital Firms in Zhejiang” for ten years.